New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 19, 2014
10:18 EDTNFX, EEP, ASML, SNMX, CCE, HWAY, TEX, HSP, BOBEHigh option volume stocks:
High option volume stocks: HWAY ASML BOBE CCE ASHR EEP HSP SNMX NFX TEX
News For HWAY;ASML;BOBE;CCE;EEP;HSP;SNMX;NFX;TEX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
December 15, 2014
10:06 EDTBOBEBob Evans rallies as CEO steps down, levels to watch
Subscribe for More Information
05:21 EDTBOBEBob Evans CEO Steve Davis steps down
Subscribe for More Information
December 12, 2014
16:22 EDTBOBEDiscovery Capital reports 8.9% passive stake in Bob Evans
December 11, 2014
07:13 EDTHSPDanone to discuss whether to keep or sell medical nutrition unit, Reuters says
According to a source, Danone (DANOY) will hold a board meeting today to discuss whether to keep or sell its medical nutrition business, Reuters reports. Previous reports said Danone's board would decide whether to sell the unit to Hospira (HSP) or Fresenius (FMS), with Fresenius as the possible front-runner to enter exclusive talks. Reference Link
December 10, 2014
11:57 EDTNFXStocks with call strike movement; NFX FSLR
Subscribe for More Information
December 9, 2014
13:08 EDTHSPMerck may have paid $2B-$3B too much for Cubist, analyst says
Subscribe for More Information
12:30 EDTEEPWells Fargo to hold a symposium
Subscribe for More Information
08:23 EDTHSPMerck has 'no way out' of Cubist deal after court decision, says Leerink
Subscribe for More Information
08:12 EDTHSPMerck still sees Cubist acquisition neutral to modestly accretive to 2015 EPS
Merck (MRK) issued the following statement regarding the decision of the U.S. District Court for the District of Delaware. The decision, which upheld the patent for CUBICIN that expires on June 15, 2016 and invalidated four others, is subject to appeal. The company continues to believe the acquisition of Cubist (CBST) will create strong fundamental value for Merckís shareholders. The combined strength of both companies will provide both incremental and long-term value, and Merck expects the transaction to add more than $1B of revenue to its 2015 base, with strong growth potential thereafter. The courtís decision does not change Merckís expectation that the transaction will be neutral to modestly accretive to 2015 non-GAAP EPS. The company also continues to expect that the transaction will contribute mid-single digit accretion on a percentage basis to non-GAAP EPS in 2016, and will continue to be accretive thereafter.
07:01 EDTNFXNewfield Exploration coverage resumed with a Hold at Stifel
Subscribe for More Information
December 8, 2014
19:00 EDTHSPCubist CEO says Cubicin patent ruling will not affect Merck transaction
Subscribe for More Information
18:24 EDTHSPOn The Fly: After Hours Movers
Subscribe for More Information
18:00 EDTHSPCubist loses bid to stop Hospira's generic Cubicin after 2016, Bloomberg says
Cubist's (CBST) patent for Cubicin that expires in June 2016 upheld by judge, Bloomberg added. Note that this morning Merck (MRK) and Cubist Pharmaceuticals announced that the companies have entered into a definitive agreement under which Merck will acquire Cubist for $102 per share in cash.
17:54 EDTHSPFour Cubist Cubicin patents invalidated as Hospira wins ruling, Bloomberg says
Subscribe for More Information
17:30 EDTHSPMerck shares lower after reports of judge decision in Cubist/Hospira case
Subscribe for More Information
17:03 EDTHSPJudge may have found in favor of Hospira in Cubist case,CNBC's Meg Tirrell says
CNBC's Meg Tirrell said in a tweet: "Whoa. $CBST Hospira decision out -- "appears judge may have found in favor of Hospira on several points," ISI's @MarkSchoenebaum says." Reference Link
10:00 EDTNFX, EEPOn The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: Antero Resources (AR) upgraded to Buy from Neutral at Citigroup... Apache (APA) upgraded to Buy from Neutral at Citigroup... Applied Materials (AMAT) upgraded to Buy from Hold at Deutsche Bank... Arch Capital (ACGL) upgraded to Outperform from Market Perform at BMO Capital... CU Bancorp (CUNB) upgraded to Buy from Hold at Sandler O'Neill... Calpine (CPN) upgraded to Outperform from Neutral at Macquarie... Commerzbank (CRZBY) upgraded to Market Perform from Underperform at Keefe Bruyette... EastGroup Properties (EGP) upgraded to Neutral from Underperform at Credit Suisse... Enbridge Energy Management (EEQ) upgraded to Equal Weight at Morgan Stanley... Enbridge Energy (EEP) upgraded to Equal Weight from Underweight at Morgan Stanley... GasLog (GLOG) upgraded to Buy from Hold at Stifel... Hoegh LNG (HMLP) upgraded to Buy from Neutral at UBS... Illinois Tool Works (ITW) upgraded to Buy from Accumulate at Global Hunter... LaSalle Hotel (LHO) upgraded at Morgan Stanley... Lufthansa (DLAKY) upgraded to Buy from Neutral at Nomura... NASDAQ (NDAQ) upgraded to Outperform from Market Perform at Keefe Bruyette... Newfield Exploration (NFX) upgraded to Buy from Neutral at Citigroup... Omega Healthcare (OHI) upgraded to Buy from Hold at Jefferies... Orange SA (ORAN) upgraded to Conviction Buy from Neutral at Goldman... SM Energy (SM) upgraded to Outperform from Market Perform at BMO Capital... Southwest (LUV) upgraded at Goldman... TSMC (TSM) upgraded to Buy from Neutral at BofA/Merrill... United Technologies (UTX) upgraded at Bernstein... eBay (EBAY) upgraded to Buy from Hold at Stifel.
08:21 EDTHSPMerck says looked at all risks, including patent litgation, before Cubist deal
Subscribe for More Information
08:00 EDTEEPEnbridge Energy upgraded to Equal Weight from Underweight at Morgan Stanley
Morgan Stanley upgraded Enbridge Energy to Equal Weight from Underweight based on an improved distribution growth outlook. Price target raised to $47 from $38.
06:16 EDTNFXNewfield Exploration upgraded to Buy from Neutral at Citigroup
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use